← Leaderboards
Norbert Pardi
University Of Pennsylvania
$13,084,354
Attributed
$16,536,160
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.3M · FY2019–25$10M$7.5M$5M$2.5M$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,536,160 · 5
By mechanism
R01$7,724,982 · 3
U01$4,857,475 · 1
U19$3,953,703 · 1
Top collaborators
- Caius Gabriel Radu2 shared
- Michela Locci1 shared
- Ting-Ting Wu1 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Mark L Kahn$46,704,160
- Edward E Morrisey$54,694,196
- Warren S Pear$28,448,095
- Edward M Behrens$6,055,208
- Drew Weissman$21,263,557
Others in their field
Other Emerging Leaders on “Messenger Rna”
- Laura McNay · Leidos Biomedical Research, Inc.$15,147,252
- Neil King · University Of Washington$12,677,393
- Kirsten Frieda · Spatial Genomics, Inc.$12,006,066
- Wilton B Williams · Duke University$11,389,307
- Julie Ake · National Institute Of Allergy And Infectious Diseases$10,950,000
- Yunda Huang · Fred Hutchinson Cancer Center$8,398,240
Research focus
Messenger RnaAntigensVaccinesImmunizationAntibody ResponseImmune ResponseLipid NanoparticleDendritic CellsReactionStructure Of Germinal Center Of Lymph NodeCommunicable DiseasesB-LymphocytesNovel VaccinesHelper-Inducer T-LymphocyteNucleosidesVirusAnimalsIn VitroImmuneProductionEncapsulatedImmunityClinical TrialsImmunogenicity
Grant awards (14)
Strategically Engineered Multi-Antigen KSHV Vaccine: Integrating Humoral and Cellular Immunity for Effective Protection$4,857,475
U01 · FY2025 · CA
Lipid nanoparticle adjuvants for mRNA vaccines: composition-function relation and mechanism of action$803,514
R01 · FY2025 · AI · contact PI
Innovative mRNA vaccines to enhance the efficacy of T-cell transfer therapies against solid tumors$614,124
R01 · FY2025 · CA
Project 2: mRNA vaccine development against Bunyaviruses, Paramyxoviruses and Picornaviruses$3,953,703
U19 · FY2024 · AI · contact PI
Innovative mRNA vaccines to enhance the efficacy of T-cell transfer therapies against solid tumors$628,499
R01 · FY2024 · CA
Lipid nanoparticles as novel adjuvants inducing effective T follicular helper cell and humoral immune responses$708,799
R01 · FY2023 · AI · contact PI
Development of Universal Influenza Virus Vaccines Using Nucleoside-Modified Messenger RNA$613,686
R01 · FY2023 · AI · contact PI
Lipid nanoparticles as novel adjuvants inducing effective T follicular helper cell and humoral immune responses$626,397
R01 · FY2022 · AI · contact PI
Development of Universal Influenza Virus Vaccines Using Nucleoside-Modified Messenger RNA$613,686
R01 · FY2022 · AI · contact PI
Lipid nanoparticles as novel adjuvants inducing effective T follicular helper cell and humoral immune responses$633,178
R01 · FY2021 · AI · contact PI
Development of Universal Influenza Virus Vaccines Using Nucleoside-Modified Messenger RNA$610,421
R01 · FY2021 · AI · contact PI
Lipid nanoparticles as novel adjuvants inducing effective T follicular helper cell and humoral immune responses$622,103
R01 · FY2020 · AI · contact PI
Development of Universal Influenza Virus Vaccines Using Nucleoside-Modified Messenger RNA$609,757
R01 · FY2020 · AI · contact PI
Development of Universal Influenza Virus Vaccines Using Nucleoside-Modified Messenger RNA$640,818
R01 · FY2019 · AI · contact PI